Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives
-
By
-
Lingyu Jiang
-
Jiaping Wei
-
Junqi Qin
-
Jing He
-
Shengjing Liang
-
Jianwei Huang
-
Yunzhi Ma
-
Yifan Zhou
-
Yonglong Zhong
-
June 10, 2026
-
Clinical Scorecard: Efgartigimod in the Treatment of Generalized Myasthenia Gravis: An In-Depth Analysis of Clinical Evidence and Future Directions
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Neonatal Fc receptor (FcRn) antagonist that accelerates the catabolism of IgG subclasses, including pathogenic autoantibodies. |
| Target Population | |
| Care Setting | |
Key Highlights
- Efgartigimod demonstrated rapid, clinically meaningful improvements in MG-ADL scores in AChR-Ab+ patients.
- Long-term studies confirmed reproducible efficacy and sustained safety across multiple treatment cycles.
- Real-world evidence supports rapid response and steroid-sparing effects in diverse patient populations.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of gMG should consider the presence of pathogenic IgG autoantibodies.
Management
- Efgartigimod is recommended for AChR-Ab+ gMG patients, especially those with refractory disease.
Monitoring & Follow-up
- Monitor MG-ADL scores and total IgG levels to assess treatment response.
Risks
- Monitor for treatment-emergent adverse events such as headache and nasopharyngitis.
Patient & Prescribing Data
Patients with generalized myasthenia gravis, including AChR-Ab+, antibody-negative, and those with thymoma-associated MG.
Efgartigimod has shown consistent benefits across various patient subgroups and settings.
Clinical Best Practices
Related Resources & Content
